AKT1 and prostate carcinoma: Research by Yamamoto and colleagues showed that a single dose of sorafenib (30-60 mg/kg) decreased the activation of the PI3K/AKT/mTOR signaling axis in a mouse model of PTEN-deficient prostate cancer (20).